This one is taken by mouth, not as an injection
Ruschak I, Montes-Curto P, Rossell L, Aguilar Martn C,Snchez-Montes L, Toussaint L
Sa and her colleagues say that further research is needed to tease apart whether the benefits from GLP-1s among people with schizophrenia are the result of direct neuropsychotropic effects or indirect benefits from their metabolic and anti-inflammatory effects
For patients with chronic kidney disease (CKD) or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit should be considered GLP-1 receptor agonists are generally recommended as the first injectable medication, except in settings where type 1 diabetes is suspected Intensification of treatment beyond dual therapy to maintain glycaemic targets requires consideration of the impact of medication side-effects on comorbidities, as well as the burden of treatment and cost The panel say that the lack of evidence over specific combinations of glucose-lowering therapies remains an issue, and more research is needed
MingroneGPanunziSDe GaetanoAGuidoneCIaconelliANanniGet al